Myrthe Mampay

Feb 9, 2024 | onlinelibrary.wiley.com | Daniela Magalhães |Nicolas A. Stewart |Myrthe Mampay |Sara O. Rolle

1 INTRODUCTION FTY720, also known as fingolimod, was approved in 2010 by the US Food and Drug Administration (FDA) and became the first oral treatment for relapsing–remitting multiple sclerosis (MS). It is a synthetic compound based on a sphingosine-like fungal metabolite known as ISP-1 (myriocin; 2S-amino-3R,4R-dihydroxy-2-(hydroxymethyl)-14-oxo-6E-eicosenoic acid) and is marketed and sold under the brand name, Gilenya.